Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 23, 2014

RRMS Treatment from Antisense Highly Effective in Clinical Trials

antisenseFor the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy. As a result, if trials continue and ATL1102 is brought to market, a new, highly effective treatment will be available that lacks the limitations of some current treatments.
“There are a number of unresolved issues with current multiple sclerosis drugs including the occurrence of neutralising antibodies to the antibody, protein, and peptide multiple sclerosis drugs as well as long-time safety concerns with the more recently approved drugs,” said Volker Limmroth, MD, PhD, of the University of Cologne, who was lead author of the study published in Neurologyin a news release. “There is a clear need for more effective and safe drugs for the significant population of multiple sclerosis patients who have relapses and non-stable disease.”
Dr. Limmroth, along with colleagues, published the results of the phase 2a trial under the title, “CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapse-Remitting MS.” A total of 77 patients were enrolled in the study, and all had relapsing-remitting multiple sclerosis. After only two months of dosing, ATL1102-treated patients showed a significantly lower cumulative number of new active brain lesions compared to placebo-treated patients.
Continue reading

 Keep CURRENT and up to date, with MS News and Information
Sign-up for our Bi-Monthly eNewsletters 



No comments: